Diamyd Medical Ab Stock Number Of Shares Shorted
| DMN Stock | EUR 1.12 0.05 4.67% |
Diamyd Medical AB fundamentals help investors to digest information that contributes to Diamyd Medical's financial success or failures. It also enables traders to predict the movement of Diamyd Stock. The fundamental analysis module provides a way to measure Diamyd Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diamyd Medical stock.
Diamyd |
Diamyd Medical AB Company Number Of Shares Shorted Analysis
Diamyd Medical's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Diamyd Medical AB has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The number of shares shorted for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Diamyd Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 96.81 M | |||
| Shares Outstanding | 76.93 M | |||
| Shares Owned By Insiders | 35.22 % | |||
| Shares Owned By Institutions | 0.26 % | |||
| Price To Book | 5.52 X | |||
| Price To Sales | 2,594 X | |||
| Revenue | 454 K | |||
| Gross Profit | (3.95 M) | |||
| EBITDA | (98.88 M) | |||
| Net Income | (103.52 M) | |||
| Current Ratio | 5.83 X | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (0.11) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 20 | |||
| Beta | 1.91 | |||
| Market Capitalization | 99.6 M | |||
| Total Asset | 236.52 M | |||
| Net Asset | 236.52 M |
About Diamyd Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diamyd Medical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diamyd Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diamyd Medical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.